In a syngeneic model of ovarian cancer using mouse ID8 cells stably expressing the NGL NF-κB reporter plasmid, we recently showed that NF-κB activity markedly increases during abdominal cancer spread and is reduced by treatment with the promising anti-cancer drug, thymoquinone (TQ) [10]. The gene discussed is NFKB1; the disease is ovarian cancer.